A novel polymorphism in the factor XIII B-subunit (His95Arg): relationship to subunit dissociation and venous thrombosis by Komanasin, N. et al.
ORIGINAL ARTICLE
A novel polymorphism in the factor XIII B-subunit (His95Arg):
relationship to subunit dissociation and venous thrombosis
N. KOMANAS IN ,* A . J . CATTO,* T . S . FUTERS ,* A . VAN HYLCKAMA VL IEG , F . R . ROSENDAAL
and R. A. S. AR I E¨NS*
*Academic Unit of Molecular Vascular Medicine, Leeds Institute for Genetics, Health and Therapeutics, University of Leeds, UK; Department of
Clinical Epidemiology, Leiden University Medical Center, Leiden, the Netherlands; and Department of Haematology, Leiden University Medical
Center, Leiden, the Netherlands
To cite this article: Komanasin N, Catto AJ, Futers TS, van Hylckama Vlieg A, Rosendaal FR, Arie¨ns RAS. A novel polymorphism in the factor XIII
B-subunit (His95Arg): relationship to subunit dissociation and venous thrombosis. J Thromb Haemost 2005; 3: 2487–96.
Summary. Background: Factor (F)XIIIB-subunit,whichplays
a carrier role for zymogen FXIIIA, is highly polymorphic, but
the molecular basis for these polymorphisms and their relation-
ship to disease remains unknown. Objectives: To screen the
FXIIIB gene coding region for common variation and analyze
possible functional eﬀects.Methods and Results: We examined
the FXIIIB gene by PCR-SSCP and identiﬁed three common
single nucleotide polymorphisms: A8259G, C29470T and
A30899G. A8259G results in substitution of His95Arg in the
secondSushidomain.AnFXIII tetramerELISAwasdeveloped
to analyze B-subunit dissociation from A-subunit (leading to
access to the catalytic site of FXIII). Increased subunit
dissociation, 0.51 vs. 0.45 (fraction of total tetramer), was found
in plasma from subjects possessing the Arg-allele. However,
when thevariantswerepuriﬁed tohomogeneityandbindingwas
analyzed by steady-state kinetics, no diﬀerence was observed.
The relationship betweenHis95Arg andvenous thrombosiswas
investigated in 214 patients and 291 controls from Leeds. His/
Arg + Arg/Arg genotypes weremore frequent in patients than
controls (22.4% vs. 15.1%). His95Arg was also investigated in
the Leiden Thrombophilia Study, in which a similar diﬀerence
was observed for 471 patients vs. 472 controls (18.5% vs.
14.0%), for a pooled odds ratio (OR) of 1.5 (CI95 1.1–2.0).
Conclusions: We have identiﬁed three FXIIIB polymorphisms,
one of which codes for substitution of His95Arg. The Arg95
variant associates with a moderately increased risk for venous
thrombosis, and with increased dissociation of the FXIII
subunits in plasma, although in vitro steady-state binding
between puriﬁed subunits was not aﬀected.
Keywords: FXIII B-subunit, polymorphism, Sushi domain,
venous thrombosis.
Introduction
Factor XIII (FXIII) is a protransglutaminase that on
activation by thrombin catalyses the formation of e-(c-
glutamyl)-lysine bonds in polymerized ﬁbrin. The cross-linking
of ﬁbrin renders the clot chemically and mechanically more
stable as well as resistant to ﬁbrinolysis [1,2]. In the
circulation, FXIII appears as a heterotetramer of two
A- and two B-subunits that are non-covalently associated,
designated as A2B2 [1,2]. The active site of the enzyme is
located in the A-subunit. FXIII is activated by cleavage of the
peptide bond between Arg37 and Gly38 of the A-subunit
followed by subsequent dissociation of the B-subunit from the
A-subunit in the presence of Ca2+ [3,4]. Both steps are
necessary to provide access of the substrate to the catalytic
triad of FXIII and are enhanced by the presence of the main
substrate polymerized ﬁbrin. The B-subunit has no enzymatic
activity and is involved in stabilization of the A-subunit in the
aqueous environment of human plasma [5,6]. It is composed
of 641 amino acids divided into 10 tandem repeats of about 60
amino acids each, which are called GPI structures or Sushi
domains [7,8]. Each Sushi domain is encoded by a single exon
[9]. The function of these domains has yet to be fully
established although they are thought to serve mainly as
protein-binding module [8].
The B-subunit has been shown to be highly polymorphic
using protein phenotyping techniques such as isoelectric focus-
ing and agarose gel-electrophoresis [10–17], but the molecular
genetic basis of these polymorphisms and any relation to
disease has not yet been reported. We therefore (i) screened the
FXIII B-subunit gene exons coding for the Sushi domains
for polymorphisms, (ii) examined functional effects of the
polymorphism(s) using a novel FXIII A2B2 tetramer ELISA
to study A- and B-subunit dissociation in both plasma and
puriﬁed systems, and (iii) investigated associations with
vascular risk in two case–control studies of venous thrombosis.
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Materials, methods and subjects
Polymorphism identification
Standard polymerase chain reaction (PCR) was used to
amplify DNA from 12 coding regions of the FXIII B-subunit
gene. Oligonucleotides were designed based on the genomic
FXIII DNA sequence [9] obtained from GenBank using
Primer version 0.5 (Whitehead Institute for Biochemical
Research, Cambridge, MA, USA) with the primer positioned
outside the region of interest. Primers for exon I and XII also
included the 5 and 3¢ untranslated regions of the gene,
respectively. Optimal PCR conditions for each pair of primer
are available from the authors on request. PCR-single strand
conformation polymorphism (SSCP) analysis [18] using MDE
gel solution (Flowgen, Leicestershire, UK) was used to screen
DNA for polymorphisms in each region of the FXIIIB gene.
Four running conditions (with or without 10% glycerol; at
4 C or room temperature) were carried out to maximize
detection rate of SSCP. DNA sequencing was conducted to
characterize the nucleotide substitution associated with the
polymorphisms that had been detected by PCR-SSCP. The
sequencing reactions were performed using ABI PrismTM
BigDye terminator Cycle sequencing Ready Reaction kit and
analyzed on an ABI 310 automated DNA sequencer (Applied
Biosystems, Foster City, CA, USA). The His95Arg genotype
was further detected by restriction analysis using Nsi I (2 units
at 37 C, overnight incubation). The Arg allele is associated
with the loss of the Nsi I restriction site. For the His allele, the
264 bp fragment was cut into 135 and 129 bp fragments. The
difference of 6 bp between these two digested fragments was
not resolved on a 1.5% agarose gel, but all the genotypes were
readily distinguishable by identiﬁcation of the 264 bp fragment
and the 135/129 bp doublet.
FXIII A- and B-subunit antigen and FXIII activity assay
FXIII A- and B-subunit antigen levels were determined using
subunit-speciﬁc ELISAs developed in-house [19]. FXIII activ-
ity was measured using a microtiter assay using ﬁbrinogen and
5-(biotinamido)pentylamine as substrates as previously des-
cribed [19].
FXIII A2B2 tetramer antigen assay
An ELISA based on an anti-FXIIIB/anti-FXIIIA antibody
sandwich principle was developed tomeasure the levels of A2B2
complex of FXIII. The sugar moiety of a polyclonal rabbit
antihuman FXIII A antibody (Diagnostica Stago, Asnie`res,
France) was labeled with biotin-e-amino-caproyl hydrazide
(BACH) according to the method of O’Shannessy [20].
Optimization of the ELISA was carried out by varying
concentrations of the polyclonal rabbit antihuman FXIIIB
antibody (Diagnostica Stago) used for coating the plates, the
biotinylated anti-FXIIIA antibody for detection, the test
plasma and the normal plasma for standard curve preparation,
as well as streptavidin and bovine serum albumin (BSA)
concentrations. Under optimal conditions, 96 well-plates
(Nunc Maxisorp, Nunc A/S, Roskilde, Denmark) were coated
with 1/600 ﬁnal dilution of anti-FXIIIB antibody in
50 mmol L)1 sodium carbonate pH 9.6. Plates were washed
ﬁve times with 200 lL 50 mmol L)1 Tris–HCl, 0.1 mol L)1
NaCl, pH 7.5 (Tris buffered saline or TBS) with 0.1% Tween-
20, followed by blocking of non-speciﬁc-binding sites with
150 lL TBS containing 1% BSA. A range of dilutions of
reference normal pooled plasma were made in TBS with 0.3%
BSA. Test and control samples were diluted 1/400 and a total
of 100 lL was loaded in duplicate. The plate was washed ﬁve
times before applying 100 lL of biotinylated anti-FXIIIA
antibody (1/500). Antibody–antigen sandwiches were detected
by addition of 100 lL of 1/500 streptavidin conjugated with
alkaline phosphatase (Sigma, St Louis, MO, USA). Bound
conjugate was developed with 100 lL of p-nitrophenol phos-
phate (Sigma). The reaction was stopped with 100 lL
4 mol L)1 NaOH and absorbence was read at 405 with
550 nM as a reference ﬁlter. Levels of FXIIIA2B2 complexwere
expressed in percentage of pooled normal plasma. Intra-assay
CVwas 5.2% (n ¼ 20) and inter-assay CVwas 6.8% (n ¼ 14).
Puriﬁed FXIII A- and B-subunits were obtained from Diag-
nostica Stago and analyzed for speciﬁcity of the assay.
FXIII A2B2 dissociation
Dissociation of FXIII A2B2 complex was determined by
measuring levels of the complex before and after activation
with a controlled amount of thrombin and calcium. Each test
plasma sample was diluted 1/10 in TBS with 0.3% BSA
containing 0.4% Gly-Pro-Arg-Pro-amide (Sigma) to prevent
unwanted polymerization of ﬁbrin. Five microliters of a
mixture of 5 U mL)1 bovine thrombin (Sigma) and
0.5 mol L)1 CaCl2 was added to 50 lL of diluted plasma.
The mixtures were incubated at room temperature for 30 min
and the dissociation reaction was stopped with 0.1 mol L)1
trisodium citrate. Samples were further diluted 1/4 and the
remaining A2B2 complex was measured by ELISA as described
above. Control experiments were performed as follows: (i)
0.5 mol L)1 CaCl2 with TBS, (ii) 5 U mL
)1 thrombin with
TBS and (iii) TBS alone. The fraction of A2B2 complex that
was dissociated upon limited thrombin/calcium activation was
expressed as [A2B2 concentration before activation] ) [A2B2
concentration after activation]/[A2B2 concentration before
activation], the value of which is >0 and <1.
Purification of FXIII A-subunit
The FXIII A-subunit was puriﬁed from outdated platelet
concentrates of mixed, unknown genotype obtained from the
regional blood transfusion center. A quantity of 1 mmol L)1
EDTA was added to the platelet concentrates and platelets
were further isolated by centrifugation at 3400 g for 20 min at
4 C. Platelets were washed twice with Ca2+ free Tyrode’s
buffer containing 1 lg mL)1 prostacyclin, and snap-frozen in
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liquid nitrogen until use. Frozen platelets were thawed,
resuspended in 50 mmol L)1 Tris–HCl pH 7.5 containing
1 mmol L)1 EDTA, 2 mmol L)1 benzamidine and 1 lg mL)1
aprotinin, and were sonicated twice at maximum power for
15 s on ice. The lysate was centrifuged at 14 000 g for 2 h at
4 C to eliminate particulates and was further dialyzed against
equilibration buffer (20 mmol L)1 Tris–HCl, 1 mmol L)1
EDTA, 1 mmol L)1 EGTA and 5 mmol L)1 2-mercaptoeth-
anol, pH 7.5), overnight with one change of buffer. The
preparation was subjected to anion exchange chromatography
(DEAE Sephacel, Sigma; 26 · 400 mm column) on a BioCAD
SPRINT automated chromatography system (PerSeptive Bio-
systems, Framingham, MA, USA). FXIII A-subunit was
eluted with a gradient from 0 to 0.5 mol L)1 NaCl in
equilibration buffer. Fractions containing A-subunit were
combined and concentrated in dialysis membranes on Aqua-
cide II (Calbiochem, Merck Biosciences Ltd, Nottingham,
UK), and subjected to gelﬁltration on Sephadex G200 (Amer-
sham Biosciences, Bucks, UK). Combined fractions containing
A-subunit were concentrated and further puriﬁed using
hydrophobic interaction chromatography (POROS 20HP2;
4.6 · 100 mm; PerSeptive Biosystems). After washing the
columnwith equilibration buffer containing 0.5 mol L)1NaCl,
the A-subunit was eluted with a linear gradient of 0–60%
ethylene glycol in equilibration buffer. Homogeneity of the
A-subunit preparation was analyzed by SDS-PAGE. Protein
concentration was measured at 280 nM using an extinction
coefﬁcient of E1mgmL
1
280 nm ¼ 1.38 [21].
Purification of FXIII B-subunit His95 and Arg95 variants
FXIII A2B2 tetramer was puriﬁed to homogeneity from
single plasma donations of homozygous His95 (150 mL)
and homozygous Arg95 (100 mL) genotypes using repeated
ammonium sulfate precipitation and gelﬁltration as previ-
ously described [22]. FXIII B-subunit was further isolated
from these plasma FXIII preparations by anion exchange
chromatography on a POROS 20 PI column (4.6 · 100 mM;
PerSeptive Biosystems) connected to the BioCAD SPRINT.
The preparations were dialyzed against 50 mmol L)1 Tris–
HCl pH 7.5 containing 1 mmol L)1 EDTA and dissociation
of B-subunit from the FXIII A2B2 complex was induced by
incubation with 0.5 mol L)1 CaCl2 for 30 min at 37 C
prior to application to the column. The non-bound fraction
containing free B was washed from the column with
50 mmol L)1 Tris–HCl pH 7.5 containing 1 mmol L)1
EDTA and the bound fraction containing A2 and remaining
A2B2 was eluted (and discarded) with 10% acetic acid. Non-
bound B-subunit fractions were pooled and dialyzed against
3L of TBS with 0.1% BSA with three changes of buffer to
eliminate residual CaCl2. Purity of the preparation was
tested with SDS-PAGE and concentration was measured by
absorbency at 280 nM using an extinction coefﬁcient of
E1mgmL
1
280 nm ¼ 1.38, although it was recognized that this
extinction coefﬁcient is speciﬁc for FXIII A2B2 tetramer,
and that it may be different for isolated FXIII B-subunit.
FXIII A–B-binding analysis
Steady-state-binding kinetics between FXIII A- and B-subunit
isolated from each His95 and Arg95 genotype was investigated
by mixing 3 lg mL)1 of puriﬁed B-subunit variants with
increasing amounts of puriﬁed A-subunit (0, 0.5, 1, 2, 3, 4, 5, 6,
7, 8 and 9 lg mL)1). The reaction mixture was incubated at
room temperature for 30 min with gentle shaking. The mixture
was diluted 1/5 in TBS with 0.3% BSA and the concentration
of A2B2 complex that had formed was determined using the
A2B2 ELISA. The amount of formed A2B2 (FXIII Bbound) at
each concentration ofA2 was expressed as the percentage of the
maximum concentration of the complex. Ligand–receptor
kinetics was applied to determine the dissociation constant
(KD) from Lineweaver–Burk plots using EnzFitter for Win-
dows version 2.0.15.0 (Biosoft, Cambridge, UK).
Subjects
DNA samples used for screening the FXIII B-subunit gene for
polymorphisms by SSCP were obtained with informed consent
from 104 healthy Caucasian subjects who attended the regional
blood transfusion center. Samples were taken according to a
protocol approved by the Leeds Teaching Hospitals (NHS)
Trust Research Ethics Committee. Analysis of the relationship
between His95Arg and FXIII measurements was performed in
plasma samples from a study including 252 subjects with
coronary artery disease and 192 healthy controls [23]. Two
case–control groups of deep vein thrombosis from Leeds and
Leiden (Leiden Thrombophilia Study or LETS) were included
to analyze the relationship of His95Arg with disease. In the
Leeds group, 214Caucasian patients with a clinical diagnosis of
venous thrombosis (deep vein thrombosis or pulmonary
embolism) attending the local anticoagulant clinic in Leeds
had been recruited as previously described [24]. Their mean age
was 61 (SD 16.5), there were 92 (43.0%) females and 122
(57.0%) males. One hundred and sixteen (54.2%) patients had
sustained DVT and 98 (45.8%) had a clinical diagnosis of
pulmonary embolism (PE). Eighty-two cases of PE had no
evidence of DVT and 16 had evidence of both DVT and PE.
Previous episodes of venous thrombosis were reported in 62
(29%) of the patients. The thrombotic events were unprovoked
in 150 (70.1%) of the patients. The remainder 64 (29.9%)
patients had one or more risk factor (surgery, malignancy,
immobilization, pregnancy, oral contraceptives or hormone
replacement therapy). Two hundred and ninety one sex- and
age-matched controls were recruited from the Local Family
Health Service Authority (FHSA) General Practice Registers.
All of them were clinically free from a personal and family
history (in ﬁrst-degree relatives) of vascular disease (arterial and
venous). Mean age was 60 (SD 15.0), and gender distribution
was 122 (41.9%) females and 169 (58.1%) males. Both patient
and control groups were from the same geographical area. The
study was approved by the United Leeds Teaching Hospitals
Trust Research Ethics Committee. For the LETS study, a total
of 474 consecutive outpatients with a ﬁrst diagnosis of deep
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vein thrombosis attending three anticoagulant clinics in the
Netherlands – Leiden, Amsterdam and Rotterdam – were
recruited as previously described [25]. All patients were younger
than 70 years (mean age 45, SD 13.7) and free of known
malignancy disease; there were 272 (57.4%) females and 202
(42.6%) males. Thrombotic events were unprovoked in 259
(54.6%) patients, whereas in 215 (45.4%) patients presence of
one or more risk factor (surgery, puerperium, trauma, immo-
bilization, pregnancy, or oral contraceptives) was recorded.
Recurrency of thrombosis occurred in 90 (19.0%) patients over
a mean follow-up of 7.3 (SD 2.7) years [26]. A total of 474 sex-
and age-matched control subjects (mean age 45, SD 13.5 with
identical gender distribution as the patients) who were friends
or partners of the patients were included. None of the control
subjects were biologically related to the patients, had a history
of VT, or had any known malignancy disorder. The study was
approved by the local medical ethics review board. For the
purposes of the current study, 471 patients and 472 controls
from LETS were available for FXIII His95Arg analysis.
Blood sample preparation
Venous blood was collected into 1.6 mg mL)1 EDTA for
DNA extraction. DNA was extracted using a Nucleon
extraction kit (Nucleon Biosciences, Coatbridge, Lanarkshire,
UK) in Leeds, and by standard local salting out procedures in
Leiden. For assays of FXIII activity and antigen levels, blood
was taken into 0.1 mol L)1 trisodium citrate, separated by
centrifugation at 2560 g for 20 min at room temperature, snap-
frozen in aliquots in liquid nitrogen and stored at )40 C until
assay. Pooled normal plasma was obtained with informed
consent from 47 healthy donors at the local blood transfusion
center, according to a protocol approved by the Leeds
Teaching Hospitals (NHS) Trust Research Ethics Committee,
and used as reference plasma throughout the study.
Statistical analysis
Levels of FXIII A-subunit, B-subunit and A2B2 complex were
not normally distributed andwere transformedwith logarithms
to allow the use of parametric statistical testing. Data were
expressed as geometric means with antilog 95% conﬁdence
intervals (CIs). FXIII activity and FXIII dissociated fraction
were expressed as means with 95% CIs. A common poly-
morphism in the FXIII A-subunit activation peptide, close to
the thrombin cleavage site, has been shown to affect rate of
FXIII activation by thrombin [22]. Interactions between
FXIIIB His95Arg, FXIIIA Val34Leu and levels of the
dissociated fraction of FXIII were investigated by regression
analysis.We calculated ORs as an estimate for relative risk, i.e.,
of the risk of venous thrombosis for those carrying the variant
allele compared with the risk of homozygous wild-type carriers.
A total of 95% CIs were based on a Poisson’s distribution and
calculated according to Woolf or derived from the models. A
pooledOR from the two studies (Leeds andLETS) was derived
by the Mantel–Haenszel method.
Results
Polymorphisms in the FXIIIB gene
All coding regions of the FXIII B-subunit gene were screened
for polymorphisms in 104 apparently healthy Caucasian
subjects. A total of three polymorphisms were detected in
these subjects by PCR-SSCP in exon III, XI and XII. Figure 1
shows the different band patterns from each of three SSCP
conditions used to identify the polymorphism in exon III. For
each polymorphism identiﬁed, the sequence change was
analyzed using two samples of each homozygote genotype
and a pair of heterozygous samples. The results showed a
substitution of A–G at nucleotide position 8259 (GenBank
1 2 3 1 2 3 1 2 3
B
A
1 2 3
Fig. 1. SSCP gels (panel A) and sequence electropherograms (panel B) demonstrating the His95Arg polymorphism found in exon III of the FXIII
B-subunit gene. Diﬀerences in bandmigrations were detected under three conditions: room temperature without glycerol (A-left), with glycerol (A-middle)
and 4 C with glycerol (A-right). A substitution of a nucleotide A (in bold) to G (in bold) at position 8259 caused a change of His to Arg at position 95 of
mature protein (1 ¼ homozygous His/His, 2 ¼ heterozygous His/Arg and 3 ¼ homozygous Arg/Arg).
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locus HUMBFXIII) in exon III, a C to T transition at
nucleotide position 29470 (GenBank locus HUMBFXIII) in
exon XI and a substitution from A–G at nucleotide 30899
(GenBank locus HUMBFXIII) in exon XII. The nucleotide
change in exon XI did not code for an amino acid change and
the change in exon XII was in the 3¢UTR of the FXIIIB gene.
The A–G transition at nucleotide 8259 of exon III resulted in a
His-Arg change at codon 95 of the mature B-subunit protein.
Optimization of the FXIII A2B2 tetramer ELISA
An in-house ELISA was developed to measure the levels of
FXIII A2B2 tetramer. Dilution of BACH-labeled-anti-FXIIIA
antibody was chosen as 1/500 and higher maximum absor-
bency was obtained by increasing developing time from 10 to
15 min. Optimal dilutions of anti-FXIIIB antibody and
streptavidin–alkaline–phosphatase were titrated at 1/600 and
1/500, respectively. To minimize background absorbency from
0.50 to 0.20, the concentration of BSA in the dilution buffer of
the assaywas increased from 0.1% to 0.3%. The dose–response
curve of the A2B2 tetramer ELISA showed a sigmoidal shape
typical for biological assays (Fig. 2A). The dilutions of pooled
normal plasma used for standard curve preparation were
chosen between 1/100 and 1/1600, within the linear part of the
dose–response curve. A dilution of 1/400 was routinely
employed for test and control plasma samples. Puriﬁed FXIII
A-subunit, B-subunit and a combination of the two were used
to test speciﬁcity of the assay. Recovery was <1% when
incubating with A- or B-subunit alone. A 1:1 molar mixture of
A- and B-subunits gave a recovery of approximately 100%.
FXIII A2B2 dissociation
Activation with thrombin and calcium signiﬁcantly reduced
FXIII A2B2 tetramer levels. Dissociation of the tetramer
started at 0.1 U mL)1 and was practically complete at
10 U mL)1 thrombin (Fig. 2B). Addition of 0.5 U mL)1
thrombin led to approximately half pre-activation levels. A
time-course of the dissociation with 0.5 U mL)1 thrombin
showed a 50% reduction in levels when incubating for 30 min
at room temperature (Fig. 2C). There was a similar increase in
subunit dissociation rate with increasing calcium concentra-
tions (data not shown). Control experiments showed that
incubation with CaCl2 alone up to 50 mmol L
)1 or TBS alone
for 30 min at room temperature did not induce dissociation of
the A2B2. Some dissociation of the A2B2 complex could be
induced by incubation with thrombin alone, or a high
concentration of CaCl2 alone (>500 mmol L
)1), but not to
the same extent as in the presence of both thrombin and CaCl2.
His95Arg and A2B2 dissociation in plasma
Of the three polymorphisms found in the FXIIIB gene,
His95Arg causes a change in the amino acid sequence and
was therefore studied further for functional effects on subunit
dissociation. FXIII activity, A2B2 antigen, subunit antigen
levels and dissociated fraction were examined in relation to
each FXIIIB His95Arg genotype. There were no differences in
FXIII activity, subunit antigen levels and A2B2 levels prior to
thrombin activation in relation to genotype. Following activa-
tion with thrombin, a genotype-speciﬁc response was observed
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Fig. 2. Development of a FXIII A2B2 tetramer ELISA. Panel A shows a typical dose–response curve of the assay. Panel B shows a dose–response
activation and dissociation of the FXIII subunits and hence disappearance of the A2B2 tetramer as analyzed by the ELISA after incubation with thrombin
and calcium. By increasing thrombin concentrations from 0.01 U mL)1, approximately half-normal levels of FXIII A2B2 were found at the concentration
of thrombin at 0.5 U mL)1. Panel C shows a time course of A2B2 complex dissociation by 0.5 U mL
)1 thrombin. A mixture of diluted plasma, thrombin
and calcium was incubated at room temperature for 5, 10, 20, 30, 40, 50 and 60 min. The complex concentration was reduced to about 50% at the
incubation time of 30 min.
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with a stepwise increase of the fraction of A2B2 that dissociated
with the number of Arg alleles (Table 1). This increase in
dissociated fraction with the number of Arg alleles was also
present after stratiﬁcationbyFXIIIAVal34Leupolymorphism.
Binding studies with purified proteins
FXIII A-subunit was puriﬁed to homogeneity from platelets
(Fig. 3). The preparation demonstrated a single band on SDS-
PAGE corresponding to that of plasma FXIII A-subunit
(Fig. 3B). His95 and Arg95 B-subunits were puriﬁed from
plasma FXIII by incubation with calcium followed by anion
exchange chromatography (Fig. 4). Figure 4B shows homo-
geneity of the B-subunit preparation by SDS-PAGE. The
steady-state binding between puriﬁed A-subunit and B-His95
and B-Arg95 subunits was investigated using a receptor–ligand
model of binding kinetics (Fig. 5). Dissociation constants (KD)
for the two forms of the FXIIIBHis95Arg polymorphismwere
calculated from the double reciprocal plots between the
concentrations of A2 and bound B2 (insets of Fig. 5). The KD
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Fig. 3. Puriﬁcation of the FXIII A-subunit from human platelets. Panel A
shows a chromatogram from the hydrophobic interaction chromatogra-
phy (ﬁnal step in the puriﬁcation procedure) and panel B shows SDS-
PAGE of protein preparations. The FXIII A-subunit eluted from the
hydrophobic interaction column between 7 and 12 min. Platelet FXIII A
was puriﬁed to homogeneity as judged by SDS-PAGE. LMWM: low
molecular weight marker. Right-hand side of the gel shows samples
reduced with 0.1 M DTT and left-hand side non-reduced samples. Plasma
FXIII produces two bands of which the top one corresponds with the
A-subunit and the bottom one with the B-subunit. Plasma FXIII A- and
B-subunit bands migrate at similar position under reducing conditions.
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Fig. 4. Puriﬁcation of FXIII B-subunit from human plasma. Panel A
shows a chromatogram of anion exchange chromatography and panel B
shows SDS-PAGE patterns on an 8% polyacrylamide gel of puriﬁed
B-subunit of FXIII. FXIII B-subunit eluted in the ﬂow-through fraction of
the anion exchange chromatography (Panel A). The preparation showed
one band on SDS-PAGE, corresponding with the B-subunit of plasma
FXIII (Panel B). The middle lane in Panel B shows plasma FXIII of
intermediate purity.
Table 1 Levels of FXIII subunit antigen, activity, A2B2 complex and dissociated fraction in relation to FXIIIB His95Arg
His/His (n ¼ 361) His/Arg (n ¼ 80) Arg/Arg (n ¼ 3)
FXIII A-subunit antigen 107.1 (103.8, 110.4) 104.8 (99.2, 110.7) 106.9 (66.0, 139.0)
FXIII B-subunit antigen 106.3 (103.8, 108.8) 106.8 (101.7, 112.0) 98.4 (81.0, 125.0)
FXIII activity 99.1 (95.3, 102.8) 103.0 (95.4, 110.5) 98.7 (64.9, 132.5)
FXIII A2B2 complex 86.4 (83.7, 89.2) 85.9 (80.7, 91.4) 104.4 (87.7, 130.8)
Dissociated fraction 0.45 (0.43, 0.47) 0.50 (0.47, 0.54) 0.52 (0.39, 0.60)
Assays were performed in a total of 444 subjects (252 patients with vascular disease and 192 controls). Levels of FXIII-A, B-subunit, activity and
A2B2 complex are expressed as percentage of normal pooled plasma. FXIII-A and B-subunit antigen data are presented as geometric mean (95%
conﬁdent interval; CI). Activity, A2B2 complex and dissociated fraction data are presented as mean (95%CI). Data for the Arg/Arg genotype are
reported as mean or geometric mean (range).
Dissociated fraction ¼ ½A2B2b½A2B2 a½A2B2 b , whereby b ¼ before; a ¼ after activation.
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of A–B interaction was not different for the His95 or Arg95
variants of B-subunit (8.06 · 10)8 vs. 8.13 · 10)8 mol L)1,
respectively).
His95Arg and venous thrombosis
The relationship between FXIIIB His95Arg and venous
thrombosis was ﬁrst investigated in a relatively small case–
control study of 214 patients with venous thrombosis and 291
control subjects from Leeds. Frequencies of the His/Arg and
Arg/Arg genotypes were greater in patients with venous
thrombosis (21.5 and 0.9%) than in controls (14.4 and 0.7%,
respectively; Table 2). The genotype distributions of His95Arg
were also investigated in a larger case–control study of patients
with venous thrombosis from Leiden (LETS). Again, the His/
Arg and Arg/Arg genotypes were more frequent among the
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Fig. 5. Steady-state-binding kinetics of puriﬁed FXIII B-subunit variants and A-subunit. Increasing concentrations (0–54 nmol L)1) of puriﬁed FXIII
A-subunit [A2]was incubatedwith38 nmol L
)1puriﬁedFXIIIHis95 (PanelA)orArg95(PanelB)B-subunitandtheamountofboundB-subunitwasmeasured
byA2B2ELISA.Datawere analyzed by double-reciprocal Lineweaver–Burkplots (insets) andﬁtted to a receptor–ligandmodel of binding kinetics to calculate
dissociation constants. No diﬀerence in dissociation constant was observed (KD 8.06 · 10)8 vs. 8.13 · 10)8 mol L)1 for His95 and Arg95, respectively).
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patients (17.2% and 1.3%) than controls (13.1% and 0.8%;
Table 1).Whenwe analyzed the effect of heterozygousHis/Arg
genotype on risk, the OR was 1.6 (CI95 1.0–2.6) for the Leeds
study, and 1.4 (CI95 1.0–2.0) in the Leiden study. Similar ORs
were observed for the homozygous Arg/Arg genotype in both
the Leeds and LETS studies (1.5 and 1.6, respectively),
although the CIs for this genotype were large because of the
small number of homozygous subjects in each group. The
pooled estimate of both studies for His/Arg genotype and
venous thrombosis led to a Mantel–Haenszel OR of 1.5 (CI95
1.1–2.0).
Discussion
We have comprehensively investigated the coding regions of
the FXIII B-subunit gene for common polymorphisms in a
population of healthy Caucasian subjects. Three polymor-
phisms were found, of which one is a novel polymorphism that
codes for a His to Arg substitution at amino acid residue 95 in
the second Sushi domain of the B-subunit. The FXIIIB Arg95
allele associated with an approximately 50% increased vascular
risk in two clinical studies of venous thrombosis, Leeds and
LETS. Increased FXIII subunit dissociation rates were
observed for the Arg95 variant under controlled limited
activation of with thrombin and calcium in plasma, although
no differences were found in steady-state-binding kinetic
analysis using puriﬁed A- and variant B-subunits.
Polymorphisms of the FXIII B-subunit were ﬁrst described
by Board in 1980 [10]. Since that initial report, several other
groups investigated phenotypic variation in FXIIIB from
serum and plasma using agarose electrophoresis and isoelectric
focussing [11–17]. Three common alleles of the FXIIIB gene –
FXIIIB*1, FXIIIB*2 and FXIIIB*3 – have been described.
Determination of the primary structure and nucleotide
sequence of the gene for FXIII B-subunit [7,9] has made it
possible to characterise polymorphisms of this protein at the
DNA level. In the present study, we have systematically
screened the coding region and adjacent 3 and 5¢ untranslated
regions of the FXIII B-subunit gene for polymorphisms and
found three common single nucleotide substitutions. The ﬁrst
polymorphism concerns a substitution of C with T at
nucleotide position 29470 (GenBank locus HUMBFXIII),
which causes no change in the amino acid sequence of the
protein and has previously been reported by Bottenus et al. [9].
The second polymorphism occurs at nucleotide position 30899
(an A–G transition), which is located in the 3¢ untranslated
region and has also been previously described [27]. The 3¢
untranslated region plays a role in determiningmRNA stability
[28] and there is the possibility that a polymorphism occurring
in this area such as A30899G may inﬂuence concentration of
the messenger and protein expression. Whether A30899G
indeed has any effect on mRNA stability is an area for further
investigation. The third polymorphism that we found is novel,
involves an A–G transition at position 8259 and results in an
amino acid change from His to Arg at codon 95 of the mature
protein (FXIIIB His95Arg). This polymorphism is relatively
common with an approximate allele frequency of 15–25% in
our subjects from the North–West of Europe.
The substitutionofHis95withArgoccurs in the secondSushi
domainof theFXIIIB-subunit.As thisdomainmaybe involved
in thebindingbetween theA-andB-subunit,we investigated the
effect of the polymorphism on A–B-subunit interactions and
binding kinetics in plasma and puriﬁed systems. An ELISA
based on anti-FXIIIB/anti-FXIIIA antibody sandwich princi-
ple was developed to test this hypothesis. The assay speciﬁcally
detects theA2B2 complex but is unable to detect either theA- or
B-subunit alone after dissociation has taken place. The use of
standard doses of thrombin to induce dissociation of the A2B2
complexcould thereforebeused togivea rough indicationof the
effects of theHis95Arg polymorphismon this process. Levels of
FXIII A-subunit antigen, B-subunit antigen andA2B2 complex
before thrombin activationwere notdifferent in plasma samples
from subjects possessing the Arg95 allele compared withHis95,
demonstrating that the substitution of His95 with Arg does not
affect protein expression and/or secretion. However, levels of
A2B2 tetramer after limited thrombin activation were signiﬁ-
cantly decreased and the calculated dissociated fraction
increased in plasma from subjects possessing the Arg95 variant
of FXIII B-subunit.
The decrease of A2B2 levels after limited thrombin activation
with the corresponding increase in dissociation indicated that
the substitution of His95 with Arg in the FXIII B-subunit
weakens the heterologous association with the A-subunit.
Additionally, as this polymorphism was found in exon III of
FXIIIB, which codes for the second Sushi domain, these results
may implicate a role for this domain in the binding of the
catalytic A-subunit to the carrier B-subunit. To investigate this
further, we puriﬁed the His95 and Arg95 variants of the FXIII
Table 2 Genotype distribution of FXIIIB His95Arg in patients with venous thrombosis and control subjects
Leeds LETS
VT Controls OR (95% CI) VT Controls OR (95% CI)
All subjects 214 291 471 472
His/His 166 (77.6) 247 (84.9) 1 384 (81.5) 406 (86.0) 1
His/Arg 46 (21.5) 42 (14.4) 1.6 (1.0–2.6) 81 (17.2) 62 (13.1) 1.4 (1.0–2.0)
Arg/Arg 2 (0.9) 2 (0.7) 1.5 (0.2–10.7) 6 (1.3) 4 (0.8) 1.6 (0.4–5.7)
Genotypes expressed as number of subjects (percentage of group total).
VT, venous thrombosis; Leeds, Leeds study; LETS, Leiden thrombophilia study.
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B-subunit from human plasma, and analyzed binding kinetics
of its association with A-subunit puriﬁed from platelets. Using
receptor–ligand kinetics, we analyzed KD for A–B interaction,
which overall was similar to that described by Radek et al. [29].
However, we found no difference in the KD for the two
B-subunit variants, indicating that the substitution of His95
with Arg has no direct effect on steady-state binding to
A-subunit. The reason for this apparent discrepancy between
our results using puriﬁed proteins and those obtained from
plasma, in which dissociation of the subunits was found to be
increased in subjects possessing the Arg allele compared with
subjects possessing the His allele, is not entirely clear. There are
several hypotheses that could provide explanation for these
apparently inconsistent ﬁndings: (i) there are no differences in
binding between the His95 and Arg95 variants and the plasma
results are a chance ﬁnding, (ii) an effect of His95Arg shows up
only in combination with other genetic or environmental
factors as present in plasma but not in a puriﬁed system, or
(iii) there are no differences in steady-state binding but in other
aspects of the dissociation reaction of the A- and B-subunits
that occur when FXIII is activated. This later hypothesis may
require further investigation using different methodologies to
investigate protein interaction/dissociation.
As conditions in a puriﬁed in vitro study are different from
those of ex vivo dissociation experiments, plasma factors other
than FXIII and ﬁbrinogen may be involved in regulating the
dissociation of the complex in plasma. Alternatively, other
polymorphisms of the FXIIIA gene may interact with the
FXIIIB His95Arg polymorphism and contribute to alterations
in the dissociation of the subunits. After adjustment for the
Val34Leu polymorphism in the FXIII A-subunit, however,
subunit dissociation in plasma samples containing the Arg95
variant of B-subunit remained increased. This indicates that
His95Arg and Val34Leu have separate and possibly additive
effects on the activation rate of FXIII. Interactions between
FXIIIB His95Arg and other common polymorphisms of the
A-subunit may also be possible. It has been reported that
Leu564 and Tyr204 variants of the FXIII A-subunit for
example are associated with altered cross-linking activity of the
enzyme [30]. However, the relative contribution of these latter
polymorphisms to vascular risk [31] and FXIII activation rates
by linkage analysis in twins (de Lange et al., in prep.) is
negligible. Hence, although a combinatory effect with other
FXIII polymorphisms on subunit dissociation cannot be
excluded from our ﬁndings, they are unlikely to be major.
In two groups of patients with venous thrombosis from
Leiden and Leeds, similar differences in genotype distribution
of the FXIIIB His95Arg polymorphism were found, consistent
with a 50% increased risk of venous thrombosis. With an
overall frequency of the Arg95 that was slightly less in LETS
than in Leeds, there was a similar over-representation of the
allele in patients with venous thrombosis, leading to a pooled
risk estimate for venous thrombosis of 1.5 in subjects carrying
the Arg95 allele. Together, our data show the identiﬁcation of
three polymorphisms in the gene for FXIIIB, of which one
leads to an amino acid change in the second Sushi domain of
FXIII B-subunit of His95 to Arg. The substitution of His95
with Arg increases FXIII subunit dissociation under limited,
controlled activation conditions in plasma and associates with
a moderately increased risk for venous thrombosis.
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